Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 6/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.44 |
| ▸ | WNT1 | P04628 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | CLK3 | P49761 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181499 | 0.78 | HDAC2 (0.59) | HDAC2TBK1HDAC3DYRK1AWNT1 | |
| SCHEMBL20163063 | 0.77 | HDAC3 (0.59) | HDAC2HDAC3HDAC10 | |
| SCHEMBL4579839 | 0.75 | HDAC3 (0.61) | HDAC2HDAC3DYRK1AWNT1GSK3B | |
| SCHEMBL2132124 | 0.73 | DRD2 (0.49) | HDAC2DYRK1AWNT1 | |
| SCHEMBL20163034 | 0.72 | HDAC3 (0.58) | HDAC2HDAC3SMN1; SMN2 | |
| SCHEMBL20181500 | 0.72 | HDAC2 (0.84) | HDAC2HDAC3HDAC10 | |
| SCHEMBL28315510 | 0.71 | HDAC2 (0.67) | HDAC2HDAC3DYRK1AWNT1GSK3B | |
| SCHEMBL20163097 | 0.70 | HDAC2 (0.70) | HDAC2HDAC3DYRK1AWNT1GSK3B | |
| SCHEMBL20163014 | 0.70 | TBK1 (0.50) | TBK1 | |
| SCHEMBL20163164 | 0.70 | HDAC3 (0.58) | HDAC2HDAC3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2020-12-03 | — | — | US | disclosed |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2019-10-31 | — | — | US | disclosed |
| US-10385031-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385031-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | HDAC2 2/4885TBK1 2876/4885HDAC3 7/4885 |
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | HDAC2 2/4885TBK1 3275/4885HDAC3 8/4885 |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | HDAC2 2/4885TBK1 2693/4885HDAC3 6/4885 |
| US-10774056-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | HDAC2 2/4885TBK1 2844/4885HDAC3 7/4885 |
| US-20200377465-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | HDAC2 2/4885TBK1 2948/4885HDAC3 7/4885 |
| US-20190330169-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | HDAC2 2/4885TBK1 2693/4885HDAC3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.